Obesity drug semaglutide tested for brain benefits in new trial
NCT ID NCT07592546
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 4 trial will study 240 adults aged 35-55 with class I/II obesity to see if weight loss from semaglutide (Ozempic/Wegovy) improves brain health. Participants will take the drug weekly for 80 weeks and undergo MRI scans, cognitive tests, and blood work. The study also includes a lean control group for comparison. The goal is to understand how excess body fat affects the brain and whether weight loss can reverse any abnormalities.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- semaglutide (Ozempic, Wegovy)
- What this could lead to
- If successful, this could show that weight loss with semaglutide improves brain structure and function, pointing toward a way to protect brain health in people with obesity.
- What could go wrong
- This is an early-phase study focused on measuring changes, not proving clinical benefit. The results may not apply to everyone, and semaglutide can cause side effects like nausea and vomiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASS I/II OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Montreal Neurological Institute-Hospital
Montreal, Quebec, H3A 2B4, Canada